J
James Kavanagh
Researcher at University of Oxford
Publications - 36
Citations - 1189
James Kavanagh is an academic researcher from University of Oxford. The author has contributed to research in topics: Nanopore sequencing & Medicine. The author has an hindex of 8, co-authored 28 publications receiving 546 citations. Previous affiliations of James Kavanagh include John Radcliffe Hospital.
Papers
More filters
Journal ArticleDOI
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
Mark A. Ainsworth,Monique Andersson,Monique Andersson,Kathryn Auckland,J K Baillie,Eleanor Barnes,Sally Beer,A Beveridge,Sadia Bibi,L Blackwell,M Borak,Abbie Bown,Tim Brooks,Nicola A. Burgess-Brown,S Camara,Matthew Catton,K K Chau,Thomas Christott,Elizabeth A. Clutterbuck,Jesse Coker,Richard J. Cornall,Stuart Cox,D Crawford-Jones,Derrick W. Crook,Silvia D'Arcangelo,W Dejnirattsai,Dequaire Jmm.,S Dimitriadis,Kate E. Dingle,George Doherty,Christina Dold,Tao Dong,Susanna Dunachie,Daniel Ebner,M Emmenegger,A Espinosa,David W Eyre,Rory Fairhead,S Fassih,Conor Feehily,S Felle,Alejandra Fernández-Cid,M Fernandez Mendoza,T H Foord,T Fordwoh,D Fox McKee,John Frater,V Gallardo Sanchez,N Gent,D Georgiou,Christopher J. Groves,Bassam Hallis,P M Hammond,Stephanie B Hatch,Heli Harvala,Jennifer Hill,Sarah Hoosdally,B Horsington,Alison Howarth,Tim James,Katie Jeffery,E Y Jones,Anita Justice,F Karpe,James Kavanagh,D S Kim,R Kirton,Paul Klenerman,Julian C. Knight,L Koukouflis,Andrew J Kwok,U Leuschner,R Levin,A Linder,T Lockett,Sheila F Lumley,S Marinou,Brian D. Marsden,José William Martínez,L Martins Ferreira,L Mason,Philippa C Matthews,Alexander J. Mentzer,A Mobbs,Juthathip Mongkolsapaya,J Morrow,Mukhopadhyay Smm.,Matt J. Neville,Sarah Oakley,Marta Oliveira,Ashley Otter,K Paddon,J Pascoe,Y Peng,E Perez,Prem Perumal,Peto Tea.,H Pickford,Rutger J. Ploeg,Andrew J. Pollard,Alex J. Richardson,Thomas G Ritter,Devender Roberts,Gillian Rodger,Christine S. Rollier,Cathy Rowe,Justine K. Rudkin,Gavin R. Screaton,Malcolm G Semple,Alex Sienkiewicz,L Silva-Reyes,Donal T. Skelly,A Sobrino Diaz,L Stafford,Lisa Stockdale,Nicole Stoesser,Teresa L Street,David I. Stuart,Angela Sweed,Aimee R. Taylor,H Thraves,H P Tsang,M K Verheul,Richard Vipond,Timothy M Walker,Susan Wareing,Y Warren,Carrow I. Wells,C Wilson,K Withycombe,R K Young +130 more
TL;DR: Four commercial, widely available assays and a scalable 384-well ELISA can be used for SARS-CoV-2 serological testing to achieve sensitivity and specificity of at least 98%.
Journal ArticleDOI
Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study.
David W Eyre,Sheila F Lumley,Denise O'Donnell,Mark Campbell,Elizabeth Sims,Elaine Lawson,Fiona Warren,Tim James,Stuart Cox,Alison Howarth,George Doherty,Stephanie B Hatch,James Kavanagh,Kevin K Chau,Philip W. Fowler,Jeremy Swann,Denis Volk,Fan Yang-Turner,Nicole Stoesser,Philippa C Matthews,Maria Dudareva,Tim Davies,Robert Shaw,Leon Peto,Louise O Downs,Alexander Vogt,Ali Amini,Bernadette C. Young,Philip G. Drennan,Alexander J. Mentzer,Donal T. Skelly,Fredrik Karpe,Matt J. Neville,Monique Andersson,Andrew Brent,Nick S. Jones,L Martins Ferreira,Thomas Christott,Brian D. Marsden,Sarah Hoosdally,Richard J. Cornall,Derrick W. Crook,David I. Stuart,Gavin R. Screaton,T Peto,Bruno Holthof,O'Donnell A-M.,Daniel Ebner,Christopher P. Conlon,Katie Jeffery,Timothy M Walker +50 more
TL;DR: Risks were heterogenous across the hospital, with higher rates in acute medicine, and sporadic outbreaks in areas with few or no Covid-19 patients.
Journal ArticleDOI
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines
Jia-mei Wei,Koen B. Pouwels,Nicole Stoesser,Philippa C Matthews,Ian Diamond,Ruth Studley,Emma Rourke,D. Cook,John I. Bell,John N Newton,Jeremy Farrar,Alison Howarth,Brian D. Marsden,Sarah Hoosdally,E Y Jones,David I. Stuart,Derrick W. Crook,Tim E. A. Peto,A. Sarah Walker,David W Eyre,Tina Thomas,Daniel Ayoubkhani,Russell C. Black,Anton Felton,M.J. Crees,Joel Jones,L. Lloyd,Esther Sutherland,Emma Pritchard,Karina-Doris Vihta,George Doherty,James Kavanagh,Kevin K Chau,Stephanie B Hatch,Daniel Ebner,Lucas Martins Ferreira,Thomas Christott,Wanwisa Dejnirattisai,Juthathip Mongkolsapaya,Sarah Cameron,Phoebe Tamblin-Hopper,Magda Wolna,Rachael Brown,Richard J. Cornall,Gavin R. Screaton,Katrina A. Lythgoe,David Bonsall,Tanya Golubchik,Helen R. Fryer,Stuart Cox,K Paddon,Tim James,Thomas M. Boyd Jason R. House,Julie V. Robotham,Paul J Birrell,H. Jordan,Tim Sheppard,Graham Athey,Daniel S. Moody,Leigh Curry,P. J. Brereton,Ian Jarvis,Anna Godsmark,George Morris,Bobby Mallick,Phil Eeles,Jodie Hay,Harper C VanSteenhouse,Jessica Lee,Sean A. White,Tim S. Evans,Lisa Bloemberg,Katie Allison,Anouska Pandya,Sophie Frances Davis,David I. Conway,Margaret MacLeod,Chris Cunningham +77 more
TL;DR: In this article , the authors investigated anti-spike IgG antibody responses and correlates of protection after second doses of ChAdOx1 or BNT162b2 vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Journal ArticleDOI
Metagenomic Nanopore sequencing of influenza virus direct from clinical respiratory samples
Kuiama Lewandowski,Yifei Xu,Steven T. Pullan,Sheila F Lumley,Dona Foster,Nicholas D Sanderson,Alison Vaughan,Marcus Morgan,Nicole Bright,James Kavanagh,Richard Vipond,Miles W. Carroll,Anthony C. Marriott,Karen E. Gooch,Monique Andersson,Katie Jeffery,Tim E. A. Peto,Derrick W. Crook,A. Sarah Walker,Philippa C Matthews,Philippa C Matthews +20 more
TL;DR: While further optimization is required to improve sensitivity, this approach shows promise for the Nanopore platform to be used in the diagnosis and genetic analysis of influenza virus and other respiratory viruses.
Journal ArticleDOI
Consequences of symbiont co-infections for insect host phenotypes.
Ailsa H. C. McLean,Benjamin J. Parker,Jan Hrcek,James Kavanagh,Peter A. D. Wellham,H. Charles J. Godfray +5 more
TL;DR: The long-term maintenance of symbiont co- Infections in aphids is likely to be determined primarily by costs of co-infections and in some instances by redundancy of Symbiont benefits.